Cargando…
Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease
BACKGROUND: Sickle cell disease (SCD) is a clinically heterogeneous disease with many acute and chronic complications driven by ongoing vaso-occlusion and hemolysis. It causes a disproportionate burden on Black and Hispanic communities. Our objective was to follow the SMDM/ISPOR Task Force recommend...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9049306/ https://www.ncbi.nlm.nih.gov/pubmed/35482721 http://dx.doi.org/10.1371/journal.pone.0267448 |
_version_ | 1784696115408404480 |
---|---|
author | Johnson, Kate M. Jiao, Boshen Bender, M. A. Ramsey, Scott D. Devine, Beth Basu, Anirban |
author_facet | Johnson, Kate M. Jiao, Boshen Bender, M. A. Ramsey, Scott D. Devine, Beth Basu, Anirban |
author_sort | Johnson, Kate M. |
collection | PubMed |
description | BACKGROUND: Sickle cell disease (SCD) is a clinically heterogeneous disease with many acute and chronic complications driven by ongoing vaso-occlusion and hemolysis. It causes a disproportionate burden on Black and Hispanic communities. Our objective was to follow the SMDM/ISPOR Task Force recommendations for good practices and create a conceptual model of the progression of SCD under current clinical practice to inform cost-effectiveness analyses (CEA) of promising curative therapies in the pipeline over a lifetime horizon. METHODS: We used consultations with experts, providers, and patients to identify acute events and chronic conditions in the conceptual model. We compared our model structure to previous CEA models of interventions for SCD, assessed the prevalence of the identified disease attributes in Medicaid and Medicare claims databases, and identified relevant outcomes following the 2(nd) Panel in CEA. We determined an appropriate modeling technique and relevant data sources for parameterizing the model. RESULTS: The conceptual model structure included four dimensions of disease: chronic pain, acute events, chronic conditions, and treatment complications, spanning 26 disease attributes with significant impacts on health-related quality of life and resource. We modeled chronic pain separately to reflect its importance to patients and interaction with all other disease attributes. We identified additional data sources for health state utilities and non-medical costs and benefits of SCD. We will use a microsimulation model with age- and sex-specific transitions between health states predicted by patient demographic characteristics and disease history. CONCLUSION: Developing the model structure through an explicit process of model conceptualization can increase the transparency and accuracy of results. We will populate the conceptual model with the data sources described and evaluate the cost-effectiveness of curative therapies. |
format | Online Article Text |
id | pubmed-9049306 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-90493062022-04-29 Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease Johnson, Kate M. Jiao, Boshen Bender, M. A. Ramsey, Scott D. Devine, Beth Basu, Anirban PLoS One Study Protocol BACKGROUND: Sickle cell disease (SCD) is a clinically heterogeneous disease with many acute and chronic complications driven by ongoing vaso-occlusion and hemolysis. It causes a disproportionate burden on Black and Hispanic communities. Our objective was to follow the SMDM/ISPOR Task Force recommendations for good practices and create a conceptual model of the progression of SCD under current clinical practice to inform cost-effectiveness analyses (CEA) of promising curative therapies in the pipeline over a lifetime horizon. METHODS: We used consultations with experts, providers, and patients to identify acute events and chronic conditions in the conceptual model. We compared our model structure to previous CEA models of interventions for SCD, assessed the prevalence of the identified disease attributes in Medicaid and Medicare claims databases, and identified relevant outcomes following the 2(nd) Panel in CEA. We determined an appropriate modeling technique and relevant data sources for parameterizing the model. RESULTS: The conceptual model structure included four dimensions of disease: chronic pain, acute events, chronic conditions, and treatment complications, spanning 26 disease attributes with significant impacts on health-related quality of life and resource. We modeled chronic pain separately to reflect its importance to patients and interaction with all other disease attributes. We identified additional data sources for health state utilities and non-medical costs and benefits of SCD. We will use a microsimulation model with age- and sex-specific transitions between health states predicted by patient demographic characteristics and disease history. CONCLUSION: Developing the model structure through an explicit process of model conceptualization can increase the transparency and accuracy of results. We will populate the conceptual model with the data sources described and evaluate the cost-effectiveness of curative therapies. Public Library of Science 2022-04-28 /pmc/articles/PMC9049306/ /pubmed/35482721 http://dx.doi.org/10.1371/journal.pone.0267448 Text en © 2022 Johnson et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Study Protocol Johnson, Kate M. Jiao, Boshen Bender, M. A. Ramsey, Scott D. Devine, Beth Basu, Anirban Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease |
title | Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease |
title_full | Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease |
title_fullStr | Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease |
title_full_unstemmed | Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease |
title_short | Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease |
title_sort | development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9049306/ https://www.ncbi.nlm.nih.gov/pubmed/35482721 http://dx.doi.org/10.1371/journal.pone.0267448 |
work_keys_str_mv | AT johnsonkatem developmentofaconceptualmodelforevaluatingnewnoncurativeandcurativetherapiesforsicklecelldisease AT jiaoboshen developmentofaconceptualmodelforevaluatingnewnoncurativeandcurativetherapiesforsicklecelldisease AT benderma developmentofaconceptualmodelforevaluatingnewnoncurativeandcurativetherapiesforsicklecelldisease AT ramseyscottd developmentofaconceptualmodelforevaluatingnewnoncurativeandcurativetherapiesforsicklecelldisease AT devinebeth developmentofaconceptualmodelforevaluatingnewnoncurativeandcurativetherapiesforsicklecelldisease AT basuanirban developmentofaconceptualmodelforevaluatingnewnoncurativeandcurativetherapiesforsicklecelldisease |